Semaglutide (Ozempic/Wegovy) Slows Markers of Biological Ageing in Small Trial: In a 32‑week randomized study of 108 adults with HIV‑associated lipohypertrophy, weekly semaglutide injections were linked to slower biological ageing measured by DNA methylation‑based epigenetic clocks. The DunedinPACE clock indicated about a 9% slower pace of ageing, while PCGrimAge showed reductions in processes tied to disease and mortality. Results are promising but preliminary; larger and longer studies are needed to confirm broader clinical benefits.
Semaglutide (Ozempic/Wegovy) Linked to Slower Biological Aging in 32‑Week Trial
Popular weight loss drug may slow down biological aging: Study
Semaglutide, the GLP‑1 medication marketed as Ozempic and Wegovy, was associated with slower markers of biological ageing in a small randomized trial of people with HIV‑associated lipohypertrophy, according to researchers at UC San Diego School of Medicine.
Study Design
The 32‑week randomized, placebo‑controlled trial enrolled 108 adults living with HIV who had lipohypertrophy (abnormal central fat accumulation). Participants received weekly injections of semaglutide or placebo over the study period. Rather than tracking weight or glucose outcomes, investigators evaluated biological ageing using epigenetic clocks—molecular tools that estimate biological age by measuring DNA methylation patterns.
What the Researchers Measured
Epigenetic clocks offer insight into the pace of ageing and disease risk. The trial analyzed multiple clocks, including DunedinPACE (which estimates the pace of ageing) and PCGrimAge (which relates to age‑related disease processes and mortality risk). People with HIV often experience accelerated ageing driven by chronic inflammation and persistent immune activation; the team investigated whether semaglutide might alter those processes.
Key Findings
Participants who received semaglutide showed slower ageing signatures across several epigenetic clocks tied to inflammation and major organ systems (heart, brain, kidneys, liver and metabolic system). On the DunedinPACE measure, the pace of biological ageing slowed by roughly 9% in the semaglutide group compared with placebo. PCGrimAge results also suggested reductions in biological processes linked to age‑related disease and mortality.
"Semaglutide appeared to counter inflammation‑ and immune‑driven processes that can accelerate ageing in people living with HIV," said lead author Dr. Michael Corley of UC San Diego School of Medicine.
Limitations and Context
Important caveats apply: this was a relatively small, short‑term trial in a specific population (people with HIV and lipohypertrophy). While the epigenetic clock changes are promising and biologically plausible, they do not by themselves prove that semaglutide will extend lifespan or prevent specific age‑related diseases. Larger, longer studies in diverse populations are needed to confirm these findings and determine clinical implications.
Bottom line: Early evidence suggests semaglutide may reduce molecular markers of biological ageing in people with HIV‑associated lipohypertrophy, but additional research is required before drawing broad conclusions or changing clinical practice.
Help us improve.
